MRT-2359 + enzalutamide shows 100% PSA response in AR-mutant mCRPC; Phase 2 planned 2026

Monte Rosa Therapeutics, Inc.

In 14 evaluable mCRPC patients, overall DCR 64% (9/14); in AR-mutant subset (n=4), 100% PSA response rate and 100% DCR, with 2 RECIST partial responses.
Combination well tolerated with primarily Grade 1-2 GI adverse events; no new safety signals.
Company plans to initiate Phase 2 study of MRT-2359 + AR inhibitor targeting AR-mutant mCRPC patients in 2026.
Breast cancer cohort (n=6) discontinued due to insufficient activity; MRT-8102 interim Phase 1 data expected early 2026.
Updated MRT-2359 data to be presented at ASCO GU Symposium in February 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.